FDA reform hampered by lack of initial patient involvement, FDA's Schultz tells FDLI.
This article was originally published in The Tan Sheet
Executive Summary
FDA REFORM MUST FOCUS ON BOTH CONSUMER AND INDUSTRY CONCERNS, FDA DEPUTY Commissioner for Policy William Schultz suggested Sept. 5 at a Food & Drug Law Institute meeting in Washington, D.C. Schultz told FDLI that creating comprehensive, bipartisan support for FDA reform has been difficult to achieve because current legislation is based on industry proposals that do not address the concerns of consumer and patient groups.